Patil, A. J., Sarawade, R., Khedekar, D.
Prostatic hyperplasia is noncancerous growth of cells within the prostate gland. It is a progressive condition associated with prostate enlargement (vol. more than 30 ml) as it progresses it is associated with decreased urinary flow, worsening urinary symptoms and long term complications such as bleeding, acute urinary retention (AUR), infection and stones. Prostate is regulated by especially dihydrotestosteron (DHT) which binds to androgen receptor to form complex that causes intracellular events, production of growth and signaling factors that regulate cell division and proliferation of the prostate.5-α reductase inhibitors like finasteride, dutasteride decrease the production of dihydrotestosteron within the prostate which decreases the prostate volume, increases peak urinary flow rate, decreases risk of acute urinary retention. α1 adrenergic receptor antagonist like terazosin , doxazosin and tamsulosin decreases lower urinary tract symptoms and increase urinary flow rate but do not reduce the long term risk of urinary retention or need for surgical intervention .There is new interventional therapy like Transurethral Needle Ablation (TUNA) , Microwave Thermotherapy, Ethanol Injection therapy but recent advance technique like photoselective vaporization of prostate for treatment of prostatic hyperplasia disease needs an extensive insight and deep study which can be important tool in treating prostatic hyperplasia.
Prostatic Hyperplasia, Prostate, Mechanism of Action, Existing Treatment
Cite This Article
Patil, A. J., Sarawade, R., & Khedekar, D. Prostatic Hyperplasia and Existing Treatment. International Journal for Pharmaceutical Research Scholars (IJPRS), 2(4), 303-311.